SLS
NASDAQSELLAS Life Sciences Group Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings1
News · 26 weeks37-75%
2025-10-262026-04-19
Mix1190d
- SEC Filings6(55%)
- Other5(45%)
Latest news
25 items- SECSEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.DEF 14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- SECSEC Form S-3ASR filed by SELLAS Life Sciences Group Inc.S-3ASR - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – Reported Positive Phase 2 Data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025 – – $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises – NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of nov
- SECSEC Form 10-K filed by SELLAS Life Sciences Group Inc.10-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR ConferenceNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours r
- PRSELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -- Topline Data Expected in Q4 2026 – NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009 (tambiciclib), a highly selective CDK9 inhibitor in newly diagnosed, first-line acute myeloid leuk
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
- PRSELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into EuropeSupports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026, with European enrollment anticipated in Q2 2026 NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated t
- INSIDERDirector Varian John was granted 50,000 shares, increasing direct ownership by 218% to 72,900 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Van Nostrand Robert L was granted 50,000 shares, increasing direct ownership by 152% to 82,900 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Scheinberg David A was granted 50,000 shares, increasing direct ownership by 217% to 73,082 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERSVP, Chief Development Officer Cicic Dragan was granted 300,000 shares, increasing direct ownership by 116% to 557,805 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERCFO Burns John Thomas was granted 300,000 shares, increasing direct ownership by 118% to 554,327 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Kalin Katherine Bach was granted 50,000 shares, increasing direct ownership by 48% to 154,400 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- INSIDERDirector Wasman Jane was granted 50,000 shares, increasing direct ownership by 117% to 92,900 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
- PRThe $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer TechIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramble to secure proven cancer therapies before their most profitable drugs lose protection[1]. This looming $170 billion "patent cliff" has triggered a massive capital rotation into de-risked platforms that can reach patients and the market within the next 18 to 24 months[2]. This urgent race for registration-ready assets is driving the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), OS Therapies Inc. (NY
- SECSELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
- PRSELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the final analysis is event-driven, and SELLAS will announce the occurrence of the 80th event NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided an update on the ongoing Phase 3 REGAL trial evaluating GPS as a potential maintenance therapy in patients with AML after second complete r
- PRPrecision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market SurgeVANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physicians combat cancer's most resistant forms. Targeted therapies and immunotherapies are increasingly offering viable alternatives to chemotherapies that have stood for decades as treatment mainstays[2], replacing blunt cytotoxic approaches with precision mechanisms that attack cancer cells while preserving healthy tissue. This pivot toward precision efficacy drives the investment thesis for GT Biopharma, Inc. (NASDAQ:GTBP), Lyell Immunopharma, Inc. (NASDAQ:
- PRSELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following prior VEN-based treatmentMedian overall survival (mOS) of 8.9 months in the least pretreated patient cohort; across all cohorts, mOS was not yet reached in patients with one prior line of therapy vs historical benchmark of approximately 2.5 monthsSLS009 30 mg IV twice weekly added to AZA/VEN was safe and feasible, with no dose-limiting toxicities (DLTs) observedStudy expansion to evaluate SLS009 plus AZA/VEN in newly diagnosed AML with high-risk features is p
- INSIDERSVP, Chief Development Officer Cicic Dragan disposed of $95,700 worth of shares (63,800 units at $1.50), decreasing direct ownership by 20% to 257,805 units (SEC Form 4)4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)